...
机译:P3.02C-081用Nivolumab治疗的晚期非小细胞肺癌患者的预测因素完成血液计数参数
Internal Medicine University of Miami Miller School of Medicine;
Internal Medicine University of Miami Miller School of Medicine;
Hematology-Oncology University of Miami Miller School of Medicine;
Hematology-Oncology University of Miami Miller School of Medicine;
Hematology-Oncology University of Miami Miller School of Medicine;
University of Miami Miller School of Medicine;
Hematology-Oncology University of Miami Miller School of Medicine;
Hematology-Oncology University of Miami Miller School of Medicine;
Hematology-Oncology University of Miami Miller School of Medicine;
Hematology-Oncology University of Miami Miller School of Medicine;
Hematology-Oncology University of Miami Miller School of Medicine;
Hematology-Oncology University of Miami Miller School of Medicine;
机译:P3.02C-081用Nivolumab治疗的晚期非小细胞肺癌患者的预测因素完成血液计数参数
机译:血细胞计数指数作为患有水肺治疗的先进非小细胞肺癌患者结果的预测因子
机译:P2.01-067 CEA和CYFRA21-1作为Nivolumab治疗的晚期非小细胞肺癌(NSCLC)患者的预测因子的相关性
机译:基因表达谱预测晚期非小细胞肺癌患者的生存
机译:表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物:随机对照试验的系统评价。
机译:尼古鲁单抗治疗晚期非小细胞肺癌患者中抗生素的使用血浆瓜氨酸和血液微生物组的作用
机译:内脏脂肪面积的影响作为Nivolumab治疗晚期非小细胞肺癌患者的独立预测因素